Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression profiling in OVCAR8 cells following treatment with relaxin-2 (RLN2)

ABSTRACT: Expression profiling in OVCAR8 cells following treatment with relaxin-2 (RLN2)

PROVIDER: PRJNA635380 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11856101_1.fastq.gz	Fastqsanger.gz
	SRR11856101_2.fastq.gz	Fastqsanger.gz
	SRR11856102_1.fastq.gz	Fastqsanger.gz
	SRR11856102_2.fastq.gz	Fastqsanger.gz
	SRR11856103_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Expression profiling in OVCAR8 cells following treatment with relaxin-2 (RLN2)

Project description:The relaxin-RXFP1 signaling loop promotes survival and proliferation in a panel of high-grade serous ovarian (HGSOC) cancer cell lines. Knockdown of either the relaxin receptor-1(RXFP1) or relaxin-2 (RLN2) decreased growth and tumorigenicity and increased apoptosis in dependent HGSOC cell lines. Transcriptome profiling of relaxin-dependent HGSOC cells using RNA-Seq revealed genes with altered expression levels following relaxin treatment. This included components of the Notch signaling pathway (NOTCH1 and NOTCH3), Wnt signaling (DVL1, LRP5, BCL9) and extracellular matrix regulation (VEGF-A, MMP9, MMP23). Collectively, genes and pathways upregulated by relaxin provide insight into the mechanisms by which it sustains proliferation of dependent cells.

2020-12-31 | GSE151280 | GEO

Relaxin reverses inflammatory and immune signals in aged hearts

Project description:Background: ‘Healthy’ aging drives structural and functional changes in the heart including maladaptive electrical remodeling, fibrosis and inflammation, which lower the threshold for cardiovascular diseases such as heart failure (HF) and atrial fibrillation (AF). Despite mixed results in recent clinical trials, Relaxin-therapy for 2-days could reduce mortality by 37% at 180-days post-treatment, in patients with acute decompensated HF. Relaxin’s short life-span (hours) but long-lasting protective actions led us to test the hypothesis that relaxin acts at a genomic level to reverse maladaptive remodeling in aging and HF. Methods and Results: Young (9-month) and aged (24-month), male and female F-344/Brown Norway rats were treated with relaxin (0.4 mg/kg/day) for 2-weeks delivered by subcutaneous osmotic mini-pumps or with sodium acetate (controls). The genomic effects of aging and relaxin were evaluated by extracting RNA from the left ventricles and analyzing genomic changes by RNA-sequencing, Ingenuity Pathway Analysis, MetaCore and tissue immunohistochemistry. We found that aging promotes a native inflammatory response with distinct sex-differences and relaxin suppresses transcription of multiple genes and signaling pathways associated with inflammation and HF in both genders. In addition, aging significantly increased macrophage infiltration in the ventricles and activation of the complement cascade, and relaxin reversed these age-related effects. Conclusion: These data support the hypothesis that relaxin alters gene transcription and suppresses inflammatory pathways and genes associated with HF and aging. Relaxin’s suppression of inflammation and fibrosis supports its potential as a therapy for cardiovascular and inflammation-related diseases, such as HF, AF and diabetes.

2018-01-04 | GSE106377 | GEO

Expression profiling of TNBCs following atRA treatment [Affymetrix I]

Project description:Expression profiling of TNBCs following atRA treatment [Affymetrix I]

| PRJNA482563 | ENA

Expression profiling of TNBCs following atRA treatment [Affymetrix II]

Project description:Expression profiling of TNBCs following atRA treatment [Affymetrix II]

| PRJNA483988 | ENA

Identification and Quantification of Human Relaxin Proteins by Immunoaffinity-Mass Spectrometry

Project description:We developed immunoaffinity-selected reaction monitoring assays for the measurment of human relaxin-1 and relaxin-2 proteins in biological and clinical samples.

2024-07-04 | PXD051230 | Pride

Expression data of OVCAR8 cells with and without mesothelial cells

Project description:To characterize the mesothelial cell-mediated changes of gene expression in ovarian cancer cells, we performed RNA sequencing in OVCAR8 cells with and without mesothelial cell co-culture.

2021-04-01 | GSE148033 | GEO

Identifying and overcoming a mechanism of resistance to Wee1 kinase inhibitor AZD1775 in high grade serous ovarian cancer cells (OVCAR8)

Project description:Treatment of Human high grade serous ovarian cancer cell line, OVCAR8, with WEE1 kinase inhibitor AZD1775

2020-12-01 | GSE141990 | GEO

miRNA expression profiling in cervical cancer cells following emodin treatment

Project description:miRNA expression profiling in cervical cancer cells following emodin treatment

| PRJNA559740 | ENA

miRNA expression profiling in cervical cancer cells following curcumin treatment

Project description:miRNA expression profiling in cervical cancer cells following curcumin treatment

| PRJNA556228 | ENA

CHK1 inhibition following gemcitabine treatment

Project description:CHK1 inhibition following gemcitabine treatment